adalimumab oral (PGN-OB1) / Biora Therap - LARVOL DELTA

Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery Platform (GlobeNewswire) - "Biora Therapeutics...announced preliminary results from preclinical testing of its PGN-OB1 program, reporting an average bioavailability greater than 50% for a variant of adalimumab. 'In this preclinical study, we assessed the bioavailability of a variant of adalimumab when delivered via our liquid jet injection technology in a porcine model. Following administration of 56 mg of Biora’s adalimumab variant (a dose similar to those of subcutaneously administered monoclonal antibodies), drug was detected in the blood in all animals with an average bioavailability of 51.3%, and variability similar to that seen with subcutaneous injection...These results are important, not only for the level of bioavailability, but also because of the relatively low variability, which demonstrate the potential of our liquid jet delivery technology to perform comparably to subcutaneous injection.'"

Preclinical • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis